Clinical trials: Rectal Cancers
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd
Breast Cancer, Colorectal Cancer
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
The primary objectives of this trial are to evaluate the safety and dosimetry of [68Ga]Ga-OncoFAP for detection/imaging of solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Adenocarcinoma
- Trial name
- FAPrimo (NCT05784597)
- Testing
- [68Ga]Ga-OncoFAP administration
- Where
- 5 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Philogen S.p.A.
Colo-rectal Cancer
Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy…
- Trial name
- CASCADE (NCT07148297)
- Where
- Argentina
- Volunteers
- 600 people
- Sponsor
- Epiliquid Holding, Inc
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Colonic Polyp, Colon Adenoma
Feasibility Study of a Novel Single Use Robotic Colonoscopy System
This is a single centre, non-randomized, tandem colonoscopy trial of the NISInspire-C System, followed immediately by a conventional colonoscope (CC).
- Conditions
- Colonic Polyp, Colon Adenoma, Colorectal Cancer
- Trial name
- NCT03979690
- Testing
- NISInspire-C System
- Where
- Hong Kong
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bio-Medical Engineering (HK) Limited
Colon Cancer, Rectal Cancer
Clinical Trial in Patients With Metastatic Colorectal Cancer
The objective of this trial is to compare efficacy and safety of CoFactor and 5-fluorouracil (5-FU) versus leucovorin and 5-FU in treatment of metastatic colorectal cancer.
- Trial name
- NCT00235898
- Testing
- CoFactor, 5-FU, Leucovorin
- Where
- 30 sites in India, Poland and 3 more
- Volunteers
- 300 people
- Sponsor
- Mast Therapeutics, Inc.
Colorectal Cancer
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
The purpose of this study is to determine the efficacy of an oral investigational drug in patients with refractory metastatic colorectal cancer after receiving prior therapy with 5-fluorouracil in combination with irinotecan…
- Trial name
- NCT00044343
- Testing
- lapatinib
- Where
- 57 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Metastatic Colorectal Cancer
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga…
- Trial name
- COMUNITY (NCT06557278)
- Testing
- AlloStim, Bavencio
- Where
- 3 sites in United States
- Sponsor
- Mirror Biologics, Inc.
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Metastatic Colorectal Cancer (mCRC)
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX…
- Trial name
- NCT02069704
- Testing
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- mAbxience Research S.L.
Malignant Melanoma, Colorectal Carcinoma
Safety Study of PLX4032 in Patients With Solid Tumors
The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained…
- Trial name
- NCT00405587
- Testing
- PLX4032
- Where
- 7 sites in United States, Australia
- Volunteers
- 109 people
- Sponsor
- Plexxikon
Colorectal Cancer
Safety and Immune Response to FMPV-1
This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.
- Trial name
- NCT05238558
- Testing
- FMPV-1, GM-CSF (as adjuvant)
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hubro Therapeutics AS
Anal Cancer
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus.
- Trial name
- NCT02857608
- Testing
- Lymphoseek
- Sponsor
- Cardinal Health 414, LLC
Neoplasms, Rectal
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
The main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient (dMMR)/ Microsatellite instability-high (MSI-H) rectal cancer who have…
- Trial name
- China AZUR-1 (NCT06640049)
- Testing
- Dostarlimab
- Where
- 9 sites in China
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing
In order for flexible sigmoidoscopy to be a successful screening procedure, the bowel must be free of solid matter so the endoscopist has a clear view, increasing the chance of detection of abnormalities.
- Trial name
- NCT02468726
- Testing
- NER1008 enema, Fleet
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Norgine
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Colorectal Cancer
A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer
This study was designed to investigate the safety and tolerance of three doses (100µg, 200µg, 500µg) of G17DT for the treatment of patients with colorectal cancer.
- Trial name
- CC1C (NCT02228785)
- Testing
- G17DT
- Volunteers
- 5 people
- Sponsor
- Cancer Advances Inc.
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
Colorectal cancer is the 2nd leading cause of cancer death in France. Its incidence is nearly 45,000 new cases per year in 2017, with an estimated 5-year survival of 63% in 2015.
- Trial name
- NCT05299840
- Testing
- Oncogramme results available, Oncogramme results unavailable
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Oncomedics
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.